News
2024.01.02
The biotech company DXVX is launching a genomic big data service, marking the beginning of its full-scale entry into the healthcare data business.
DX&VX announced on the 2nd that it will launch an anonymized clinical genome data service for companies and research institutes that need genome big data based on 440,000 genome analysis databases, the largest in Korea.
Through the medical information database, we provide clinical big data for medical diagnosis categorized based on criteria such as age, gender, year, region, and examination methods. The medical information encompasses clinical analysis data not only for normal individuals but also for patient groups and various rare diseases. Additionally, it contains extensive genomic information for prenatal and postnatal newborns, including embryos, amniotic fluid cells, and infants under one year old.
Companies and medical institutions requiring genomic information or analysis are expected to extract results through big data for ▲ discovery of biomarkers necessary for the development of orphan diseases and cancer treatments ▲ obtaining data required in the process of new drug development ▲ securing key data for the development of personalized treatment methods.
DXVX plans to enhance its medical data platform based on AI (Artificial Intelligence) through continued addition of genomic big data for the discovery of genetic diseases, cancer genes, and candidates for disease biomarkers, starting with the establishment of this genomic big data. Additionally, the collaboration with LG CNS and Google Cloud will be strengthened.
Through this, DXVX plans to expand its service network to domestic and international pharmaceutical companies, pharmaceutical companies, medical institutions, research institutions, and others in the future.
DX&VX official said, "Genomic big data not only includes general medical information but also vast genomic information from patient populations. For pharmaceutical companies targeting specific disease groups, this will be valuable data." They further stated, "With the initiation of this genomic big data service business, we aim to continuously secure verified medical data and expand collaborations with various global IT companies."
Source: NEWSIS